News
ALZH
0.0000
0.00%
0.00
Alzheon Advances Alzheimer’s Research with Long-term ALZ-801 Study
TipRanks · 07/31/2025 16:16
Alzheon’s ALZ-801 Study: A Promising Step in Alzheimer’s Treatment
TipRanks · 07/10/2025 16:31
Alzheon Advances ALZ-801 Study for Early Alzheimer’s Treatment
TipRanks · 07/08/2025 16:15
More
Webull provides a variety of real-time ALZH stock news. You can receive the latest news about ALZHEON, INC. through multiple platforms. This information may help you make smarter investment decisions.
About ALZH
Alzheon, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on brain health, memory and aging, and develops treatments for Alzheimer's disease and other neurodegenerative disorders. The Company's product candidate, ALZ-801 targets formation of amyloid that affects the brains of patients with Alzheimer's disease. ALZ-801 is an orally administered inhibitor of beta amyloid misfolding. It is an orally bioavailable small molecule prodrug of tramiprosate, which targets soluble amyloid-b peptides and prevents pathological aggregation and neurotoxicity that leads to neuronal cell loss and clinical decline of patients with Alzheimer's disease.